Rovi, ES0157261019

Jefferies cuts target for Rovi stock from EUR 83.50 to EUR 64.20

Published on 10/14/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies set EUR 64.20 for Rovi stock after EUR 83.50 on October 13, 2026. It costs EUR 58.35 versus a EUR 86.70 yearly high.

Analyst target and operating growth

  • Jefferies cut its Rovi target from EUR 83.50 to EUR 64.20 on October 13, 2026.
  • Operating revenue rose 9.40 percent to EUR 344.20 million in the first half of 2026.
  • Rovi stock trades at EUR 58.35 at 12:55 p.m. CEST at Lang & Schwarz on October 14, 2026.
Rovi, ES0157261019, Illustration mit AI erstellt.
Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi stock was at EUR 58.35 at Lang & Schwarz on October 14, 2026, while the 52-week range stood at EUR 53.10 to EUR 86.70. On October 13, 2026, Bolsamania reported that Jefferies cut its price target for Rovi from EUR 83.50 to EUR 64.20 while keeping a Hold recommendation.

Results set the operating baseline

Rovi's latest reported figures cover the first half of 2026. According to Estrategias de Inversion, operating revenue increased 9.40 percent to EUR 344.20 million, while net income more than doubled to EUR 84.40 million from EUR 39.70 million a year earlier.

The headline profit figure includes a EUR 62.40 million bargain purchase gain linked to the acquisition of a Bristol Myers Squibb plant in Phoenix. EBITDA rose 85.00 percent to EUR 121.20 million, but EBITDA excluding the one-off gain fell 10.00 percent to EUR 58.80 million in the first half of 2026.

What does CDMO growth mean?

Contract development and manufacturing was the clearest growth engine. Its revenue increased 38.00 percent to EUR 106.30 million in the first half of 2026, according to Estrategias de Inversion. That mix matters because Rovi also maintained its 2026 operating revenue outlook of 0.00 percent to 10.00 percent growth, leaving execution in manufacturing central to the investment case.

Next reporting date is November 5

Rovi's investor calendar lists the first nine months of 2026 financial results for November 5, 2026. The date and the first-half results headline appear on the company's investor-relations page.

Stock remains below its yearly high

At EUR 58.35, Rovi stock was 32.70 percent below the EUR 86.70 52-week high and 9.90 percent above the EUR 53.10 low on October 14, 2026. The current quote was timestamped at 12:55 p.m. CEST at Lang & Schwarz.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.

Rovi stock facts

  • Company: Laboratorios Farmaceuticos Rovi, S.A.
  • ISIN: ES0157261019
  • Ticker: ROVI.MC
  • Primary exchange: BME
  • Price Lang & Schwarz (as of October 14, 2026, 12:55 p.m. CEST): EUR 58.35
  • Market capitalization: EUR 3.0 billion (as of October 14, 2026)
  • 52-week range: EUR 53.10-86.70 (as of October 14, 2026)
  • Sector / Industry: Health Care / Pharmaceuticals
  • Index membership: IBEX 35
  • Next earnings date: November 5, 2026

Market context: Market report IBEX 35.

More news and analyses on Rovi stock

Disclaimer...

en | ES0157261019 | ROVI | boerse | 70323891 | bgmi